Perspective Therapeutics (NASDAQ:CATX) Receives $11.17 Average Price Target from Brokerages

Shares of Perspective Therapeutics (NASDAQ:CATX) have been assigned a consensus recommendation of “Buy” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $11.1667.

A number of research firms have weighed in on CATX. Truist Financial began coverage on Perspective Therapeutics in a report on Monday, November 24th. They issued a “buy” rating and a $12.00 price target for the company. BTIG Research restated a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, January 13th. UBS Group lowered their price target on shares of Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a report on Friday, November 21st. HC Wainwright boosted their price objective on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Finally, Wedbush reissued an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research report on Friday, January 30th.

Perspective Therapeutics Price Performance

Shares of NASDAQ CATX opened at $4.63 on Friday. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $6.16. The stock has a market capitalization of $344.18 million, a P/E ratio of -5.14 and a beta of 1.75. The stock has a 50-day moving average of $2.85.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds have recently bought and sold shares of the business. R Squared Ltd acquired a new position in shares of Perspective Therapeutics in the 4th quarter valued at approximately $44,000. Auctus Advisors LLC bought a new stake in shares of Perspective Therapeutics in the fourth quarter worth $87,000. Taylor & Morgan Wealth Management LLC increased its stake in shares of Perspective Therapeutics by 6.6% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company’s stock worth $267,000 after buying an additional 6,000 shares during the last quarter. Trueblood Wealth Management LLC raised its holdings in Perspective Therapeutics by 72.4% in the fourth quarter. Trueblood Wealth Management LLC now owns 119,061 shares of the company’s stock valued at $327,000 after acquiring an additional 50,000 shares in the last quarter. Finally, UBS Group AG boosted its stake in Perspective Therapeutics by 44.5% during the 4th quarter. UBS Group AG now owns 926,331 shares of the company’s stock valued at $2,547,000 after acquiring an additional 285,188 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.